<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172352</url>
  </required_header>
  <id_info>
    <org_study_id>205.139</org_study_id>
    <nct_id>NCT02172352</nct_id>
  </id_info>
  <brief_title>Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>Dose Ranging Study of Ba 679 BR Inhalation Powder Following Single Inhalation in COPD Patients - Double-blind, Placebo-controlled, 4 Treatment, 4 Period Crossover Study-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the dose response following single inhalation of Ba 679 BR inhalation powder
      in COPD patients using pulmonary functions as indicators, and to compare data obtained with
      overseas study findings
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1998</start_date>
  <primary_completion_date type="Actual">May 1999</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1.0 max (maximum forced expiratory volume in one second)</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1.0 AUC 0-24 (forced expiratory volume in one second as area under the curve 0 to 24 hours after administration)</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1.0 time to response</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1.0 Tmax (time to FEV1.0 max)</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1.0 at measuring time points up to 24 hours after administration of study drug</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC AUC 0-24 (forced vital capacity as area under the curve 0 to 24 hours after administration)</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC max</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC at measuring time points up to 24 hours after administration of study drug</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>up to 29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in pulse rate</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in transdermal O2 saturation</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal findings in electrocardiogram (ECG)</measure>
    <time_frame>before and 1.5 and 24 hours after each administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abnormal changes in laboratory measurements</measure>
    <time_frame>at 24 hours after last study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion rate</measure>
    <time_frame>before (from 4 hours pre-dosing until immediately before dosing) and 0-2, 2-4, 4-8, 8-12 and 12-24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMEF AUC 0-24 (maximal midexpiratory flow as area under the curve 0 to 24 hours after administration)</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMEF max</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MMEF at measuring time points up to 24 hours after administration of study drug</measure>
    <time_frame>before and up to 24 hours after each study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Ba 679 BR low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo inhalation powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ba 679 BR middle dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ba 679 BR high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ba 679 BR low dose</intervention_name>
    <arm_group_label>Ba 679 BR low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ba 679 BR middle dose</intervention_name>
    <arm_group_label>Ba 679 BR middle dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ba 679 BR high dose</intervention_name>
    <arm_group_label>Ba 679 BR high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo inhalation powder</intervention_name>
    <arm_group_label>Placebo inhalation powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In a pulmonary function test of Screening Test II, FEV1.0 was less than 70% of predict
             normal and FEV1.0 was less than 70% of FVC.

          2. In the reversibility test of Screening Test II, FEV1.0 was improved by 10% or more at
             1 hour after inhalation of 2 puffs of an anticholinergic agent (Tersigan ® Aerozol)

          3. History of smoking (&lt; no. of cigarettes a day x no. of years of smoking &gt; = 200 or
             more)

          4. 40 years of age or older

          5. Regardless of sex and the length of disease period

        Exclusion Criteria:

          1. A history of bronchial asthma

          2. A history of atopic disease, such as allergic rhinitis

          3. Blood eosinophil of 440/µl or more

          4. Continuous use of steroid drugs (oral administration, inhalation or injection) at a
             dose equivalent to over 5 mg daily of prednisolone

          5. A history of respiratory infection, including virus infection within 1 month before
             study initiation

          6. Tuberculosis, lung cancer or a history of pneumonectomy

          7. Glaucoma

          8. Under treatment of benign prostatic hypertrophy

          9. Hypersensitivity to anticholinergic agents or sympathomimetics

         10. Difficulty in expectoration of sputum

         11. Serious heart disease, renal disease, hepatic disease, endocrine disease or metabolic
             disease

         12. Use of any β blockers

         13. A history of myocardial infarction within the past 1 year

         14. A history of heart failure, cor pulmonale or arrhythmia requiring medication within
             the past 3 years

         15. A history of drug abuse or alcoholism

         16. Treatment of psychotic disease

         17. Pregnancy, possible pregnancy or lactation

         18. A history of participation in any other clinical studies within the past 6 months

         19. Judgment by the investigator that the patient is ineligible for inclusion in the
             present study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>June 20, 2014</last_update_submitted>
  <last_update_submitted_qc>June 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

